SUMOylation Negatively Modulates Target Gene Occupancy of the KDM5B, a Histone Lysine Demethylase
Overview
Authors
Affiliations
The histone lysine demethylase KDM5B plays key roles in gene repression by demethylating trimethylated lysine 4 of histone H3 (H3K4me3), a modification commonly found at the promoter region of actively transcribed genes. KDM5B is known to regulate the expression of genes involved in cell cycle progression; however, little is known about the post-translational modifications that regulate KDM5B. Herein, we report that KDM5B is SUMOylated at lysine residues 242 and 278 and that the ectopic expression of the hPC2 SUMO E3 ligase enhances this SUMOylation. Interestingly, the levels of KDM5B and its SUMOylated forms are regulated during the cell cycle. KDM5B is modulated by RNF4, an E3 ubiquitin ligase that targets SUMO-modified proteins to proteasomal degradation. Digital gene expression analyses showed that cells expressing the SUMOylation-deficient KDM5B harbor repressed mRNA expression profiles of cell cycle and DNA repair genes. Chromatin immunoprecipitations confirmed some of these genes as KDM5B targets, as they displayed reduced H3K4me3 levels in cells ectopically expressing KDM5B. We propose that SUMOylation by hPC2 regulates the activity of KDM5B.
LncRNA HOXC-AS3 accelerates malignant proliferation of cervical cancer cells via stabilizing KDM5B.
Li J, Hou F, Teng Z, Xia W, Peng J J Cancer Res Clin Oncol. 2024; 150(6):294.
PMID: 38842683 PMC: 11156713. DOI: 10.1007/s00432-024-05799-y.
The SUMOylation and ubiquitination crosstalk in cancer.
Li K, Xia Y, He J, Wang J, Li J, Ye M J Cancer Res Clin Oncol. 2023; 149(17):16123-16146.
PMID: 37640846 DOI: 10.1007/s00432-023-05310-z.
Di Nisio E, Licursi V, Mannironi C, Buglioni V, Paiardini A, Robusti G Cancer Gene Ther. 2023; 30(6):822-832.
PMID: 36697763 PMC: 10281864. DOI: 10.1038/s41417-022-00584-w.
Hypoxia Stimulates SUMOylation-Dependent Stabilization of KDM5B.
Zhou B, Zhu Y, Xu W, Zhou Q, Tan L, Zhu L Front Cell Dev Biol. 2022; 9:741736.
PMID: 34977006 PMC: 8719622. DOI: 10.3389/fcell.2021.741736.
Therapeutic targeting of the hypoxic tumour microenvironment.
Singleton D, Macann A, Wilson W Nat Rev Clin Oncol. 2021; 18(12):751-772.
PMID: 34326502 DOI: 10.1038/s41571-021-00539-4.